Welcome to our dedicated page for Xenetic Biosciences news (Ticker: XBIO), a resource for investors and traders seeking the latest updates and insights on Xenetic Biosciences stock.
Xenetic Biosciences Inc (NASDAQ: XBIO) is a clinical-stage biopharmaceutical leader advancing novel immuno-oncology therapies through its DNase platform and polyxen™ technology. This page provides investors and researchers with centralized access to the company’s latest developments in cancer treatment innovation.
Find timely updates on XBIO’s clinical trial progress, strategic collaborations, and regulatory milestones. Our curated collection includes press releases about orphan-designated therapies, CAR T platform advancements, and preclinical research insights – all essential for tracking the company’s contributions to targeted cancer treatments.
Key updates cover three focus areas: clinical developments in hard-to-treat cancers, technology partnerships enhancing therapeutic efficacy, and scientific publications validating novel approaches to tumor microenvironment modulation. Bookmark this page to stay informed about Xenetic’s progress in developing next-generation biologics and combination therapies.
Xenetic Biosciences (NASDAQ:XBIO) has released a Virtual Investor segment featuring Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development. The segment focuses on the company's recent poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting.
The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', highlights preclinical data in the company's immune-oncology program targeting difficult to treat cancers.
Xenetic Biosciences (NASDAQ:XBIO) has announced that its collaboration partner, PeriNess, has entered into a Clinical Study Agreement for an exploratory clinical study of XBIO-015, a systemic DNase I candidate, in patients with relapsed/refractory osteosarcoma and Ewing sarcoma.
The study, to be conducted at Tel-Aviv Sourasky Medical Center, will primarily assess safety and tolerability of XBIO-015 in combination with relapsed chemotherapy regimens. Secondary objectives include evaluating efficacy through objective response rate and progression-free survival.
Research conducted at the center between 2013-2024 revealed that neutrophil extracellular traps (NETs) in pediatric sarcomas' tumor microenvironment is a prognostic factor, with higher NETs burden correlating to poor prognosis. XBIO-015, a recombinant DNase I enzyme, works by digesting these NETs.
This initiative follows Xenetic's December 2024 agreement with PeriNess for exploratory studies of recombinant DNase in pancreatic carcinoma and other solid tumors at Israeli medical centers.
Xenetic Biosciences (NASDAQ:XBIO) reported its financial results for FY2024, highlighting progress in its DNase-based technology development for cancer treatment. The company recorded a net loss of $4.0 million, with R&D expenses decreasing 5.9% to $3.3 million and G&A expenses declining 4.1% to $3.4 million.
Key developments include extended collaborations with the University of Virginia and Scripps Research through 2025, and a new Clinical Trial Services Agreement with PeriNess for investigator-initiated studies. The company maintained stable royalty payments of $2.5 million from its Takeda Pharmaceuticals sublicense and ended the year with $6.2 million in cash.
Xenetic's focus remains on advancing its DNase-based technology toward IND and Phase 1 clinical trials for pancreatic carcinoma and other solid tumors, with preliminary preclinical studies completed in colorectal cancer models.
Xenetic Biosciences (NASDAQ:XBIO) presented positive preclinical data at the SITC Spring Scientific 2025 Cell Therapy Meeting, demonstrating the potential of DNase I as an adjunctive treatment to enhance immunotherapeutic responses.
The study investigated co-administration of DNase I with CAR T cells in a melanoma model, showing that a single injection of DNase I (10 mg/kg) with CAR T cells effectively suppressed lung metastasis at early stages. The combination treatment led to:
- Marked suppression of tumor burden
- Decreased metastatic foci
- Prolonged survival compared to CAR T cell monotherapy
- Increased tumor-infiltrating T and CAR T cells
- Reduced T cell exhaustion markers (PD-1 and TIM-3)
The company is advancing its DNase-based technology towards Phase 1 clinical trials for pancreatic carcinoma and other solid tumors.
Xenetic Biosciences (NASDAQ:XBIO) announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting. The event will be held from March 12-14, 2025, in San Diego, CA, with a virtual component.
The presentation, titled 'DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma', will be delivered by Dr. Alexey Stepanov from The Scripps Research Institute on March 12, 2025, at 5:10 p.m. PT.
Xenetic Biosciences (NASDAQ:XBIO) announced that Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development, participated in a Virtual Investor 'What This Means' segment. The segment focuses on discussing the company's recently announced extension of its Research Agreement with the University of Virginia for advancing its DNase-Based oncology platform, which aims to address hard-to-treat cancers.
Literacy Texas, a Regions Bank customer and nonprofit organization, is addressing critical literacy challenges in Texas under the leadership of Executive Director Jenny Walker. The organization serves as a support network, collaborating with over 300 nonprofits and government agencies to improve adult and family literacy through resources, training, and advocacy.
Key statistics reveal that 28% of Texas is at level one for reading, and 40% of the population reads at a third-grade level. The organization focuses on developing workforce skills, improving digital literacy, and bridging the technological divide, particularly in rural communities. Low literacy rates nationally cost the U.S. approximately $200 billion in safety and health issues and over $2 trillion in lost productivity annually.
Xenetic Biosciences (NASDAQ:XBIO) has extended its Research Funding Agreement with the University of Virginia (UVA) through 2025 to advance its DNase-based oncology platform. The program targets neutrophil extracellular traps (NETs) in the tumor microenvironment, which promote cancer spread and immunosuppression. Preclinical studies have shown that reducing NETs burden with Xenetic's recombinant human DNase I improves the efficacy of immunotherapy, adoptive cell therapy, and chemotherapy.
The company maintains an option to exclusively license new intellectual property from the research program. UVA will continue investigating DNase I combinations with immunotherapies in primary and metastatic colorectal cancer models. Xenetic is progressing toward its first-in-human study to evaluate DNase combined with immune checkpoint inhibitors or chemotherapy.
Xenetic Biosciences (NASDAQ:XBIO) has entered into a Clinical Trial Services Agreement with Israel-based PeriNess to advance its systemic DNase I oncology program. The collaboration aims to develop XBIO-015, a DNase I candidate, as an adjunctive treatment in combination with chemotherapy and immunotherapy for pancreatic carcinoma, colorectal cancer, and other advanced solid tumors.
Under the agreement, PeriNess will lead regulatory approval and manage potential exploratory studies in Israeli medical centers. The partnership leverages PeriNess' expertise in clinical development of human recombinant DNase. Preclinical data supports DNase I's role in improving therapeutic responses by targeting Neutrophil Extracellular Traps (NETs) in cancer treatment.
Xenetic Biosciences (NASDAQ:XBIO) released a Virtual Investor segment featuring Dr. Reid Bissonnette discussing recent preclinical data presented at the SITC 39th Annual Meeting. The data shows that DNase I significantly improves the effectiveness of anti-CTLA-4 immune checkpoint blockade in preclinical models of microsatellite stable/mismatch repair proficient (MSS/MMRp) colorectal carcinoma. This is particularly significant as MSS/MMRp CRC affects approximately 85% of colorectal cancer patients, a group that has historically shown response to immune checkpoint blockade treatments.
